Answers are grounded in this paper and cite their sources.
The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited. (Funded by Millennium Pharmaceuticals; TOURMALINE-MM1 ClinicalTrials.gov number, NCT01564537.).
No takes yet. Share an insight, caveat, or question.
Moreau et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: